FoxWayne Enterprises Acquisition (FoxWayne Enterprises Acquisition) Asset Impairment Charge : $0.00 Mil (TTM As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is FoxWayne Enterprises Acquisition Asset Impairment Charge?

FoxWayne Enterprises Acquisition's Asset Impairment Charge for the three months ended in Sep. 2022 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2022 was $0.00 Mil.

FoxWayne Enterprises Acquisition Asset Impairment Charge Historical Data

The historical data trend for FoxWayne Enterprises Acquisition's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FoxWayne Enterprises Acquisition Asset Impairment Charge Chart

FoxWayne Enterprises Acquisition Annual Data

Trend

Dec20

Dec21

Asset Impairment Charge

FoxWayne Enterprises Acquisition Quarterly Data
	Oct20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Asset Impairment Charge	Get a 7-Day Free Trial			-	-	-	-	-

FoxWayne Enterprises Acquisition Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

FoxWayne Enterprises Acquisition Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of FoxWayne Enterprises Acquisition's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

FoxWayne Enterprises Acquisition (FoxWayne Enterprises Acquisition) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » FoxWayne Enterprises Acquisition Corp (NAS:FOXWU) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Rockefeller Plaza, Suite 1039, New York, NY, USA, 10020

Website

https://www.foxwayne.com

FoxWayne Enterprises Acquisition Corp is a blank check company.

Executives

Robb Knie	director, officer: Chairman and CEO	C/O INVENTERGY GLOBAL, INC., 900 EAST HAMILTON AVENUE SUITE 180, CAMPBELL CA 95008
Jonathan Hale Zippin	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Foxwayne Enterprises Acquisition Sponsor Llc	director, 10 percent owner, officer: Chairman and CEO	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Michael Reavey	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Sundeep Agrawal	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Jeff Pavell	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020

FoxWayne Enterprises Acquisition (FoxWayne Enterprises Acquisition) Headlines

From GuruFocus

FoxWayne Enterprises Acquisition Corp. Announces Closing of $57,500,000 Initial Public Offering Including Full Exercise of the Underwriters' Over-Allotment Option

By PRNewswire PRNewswire • 01-22-2021

Innovative Inhaled Drug Delivery Developer Aerami Therapeutics to Merge with Special Purpose Acquisition Company FoxWayne Enterprises Acquisition Corp. to Become Public Company

By GuruFocusNews GuruFocusNews • 12-07-2021

FoxWayne Enterprises Acquisition Corp. Announces Securities to Commence Separate Trading

By PRNewswire PRNewswire • 02-26-2021

FOXWAYNE ENTERPRISES ACQUISITION CORP. ANNOUNCES CHANGE OF SPECIAL MEETING DATE AND INCREASE IN ITS CONTRIBUTION TO THE TRUST ACCOUNT FOR EXTENSION PROPOSAL

By PRNewswire PRNewswire • 11-29-2022

Innovative Inhaled Drug Delivery Developer Aerami Therapeutics to Merge with Special Purpose Acquisition Company FoxWayne Enterprises Acquisition Corp. to Become Public Company

By PRNewswire PRNewswire • 12-07-2021

Aerami Therapeutics Holdings, Inc. and FoxWayne Enterprises Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement

By PRNewswire PRNewswire • 03-04-2022

Investor Alert: The M&A Class Action Firm Announces an Investigation of the Merger of FoxWayne Enterprises Acquisition Corp. - FOXW

By PRNewswire PRNewswire • 12-16-2021

FoxWayne Enterprises Acquisition Corp. Announces Pricing of $50,000,000 Initial Public Offering

By PRNewswire PRNewswire • 01-20-2021